A Comparative Study of MRI and Ultrasound for Detection of Primary Hepatocellular Carcinoma, Body Composition and Risk Factors for Decompensation in Liver Cirrhosis

DETECT-HCC-ESLD is a prospective multicenter study designed to examine early detection and risk stratification of hepatocellular carcinoma (HCC) in individuals with advanced liver disease. Adults with cirrhosis of different etiologies are enrolled and followed longitudinally with structured clinical assessments and imaging at predefined intervals. A key objective is to evaluate ultrasound and abbreviated MRI (AMRI) as surveillance modalities for HCC. The study examines detection performance, feasibility, and factors influencing image quality and interpretability. The protocol also includes the study of body composition, focusing on how variations in adiposity and muscle mass may relate to imaging characteristics, disease progression, and HCC risk. Longitudinal clinical and imaging data are used to explore prediction models aimed at identifying patients with differing levels of HCC risk. The study records outcomes such as incident HCC, liver-related complications, and mortality to support analyses of disease trajectories. The DETECT-HCC-ESLD study provides a structured framework for collecting clinical, imaging, and body composition data over time, enabling detailed evaluation of surveillance strategies and risk patterns in advanced liver disease.

NCT Number	NCT07291141
Lead Sponsor	Mattias Ekstedt Collaborators: Antaros Medical, Amra Medical AB, Region Östergötland, Region Jönköping County, Västra Götalandsregionen, Region Stockholm, Örebro County Council, Uppsala County Council, Sweden, University Hospital, Umeå
Conditions	Liver Cirrhoses, Hepatocellular Carcinoma (HCC), Sarcopenia in Liver Cirrhosis, Portal Hypertension Related to Cirrhosis, MRI, Ultrasound
Enrollment	600 participants
Start Date	2025-12-18
Primary Completion	2029-12 (estimated)
Study Completion	2031-12 (estimated)
Updated on ClinicalTrials.gov	2025-12-19